comparemela.com

Latest Breaking News On - Edogawa evolutionary laboratory - Page 1 : comparemela.com

Global Regenerative Medicine Conference, NCRM NICHE with Fujio Cup Quiz (FCQ), E-poster and Edogawa NICHE Prize goes hybrid in 2021

Global Regenerative Medicine Conference, NCRM NICHE with Fujio Cup Quiz (FCQ), E-poster and Edogawa NICHE Prize goes hybrid in 2021
aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.

Global Regenerative Medicine Conference, NCRM NICHE with Fujio Cup Quiz (FCQ), E-poster and Edogawa NICHE Prize goes hybrid in 2021

Global Regenerative Medicine Conference, NCRM NICHE with Fujio Cup Quiz (FCQ), E-poster and Edogawa NICHE Prize goes hybrid in 2021
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

Redirecting to Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform

March 9, 2021 healthcare Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform Regenerative therapy to treat knee joint damages gets a boost with a breakthrough technology of growing ideal type of cartilage cells including chondroprogenitors and mesenchymal stem cells enriched with hyaluronic acid (HA), reported by Dr Shojiro Katoh, President, Edogawa Hospital in “The KNEE” journal (https://doi.org/10.1016/j.knee.2021.02.019). Edogawa Evolutionary Laboratory of Science (EELS) researchers accomplished this feat using a 3D tissue engineering scaffold, without externally added HA or growth factors. They hope this technology will improve the clinical outcome of Autologous Chondrocyte Implantation (ACI) and Matrix Assisted Chondrocyte Implantation (MACI) treatments.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.